Interestingly, in GBM patients presenting low levels of MGMT expression, HOXA9 overexpression alone was sufficient to identify a subset of patients with shorter OS (median OS of 291 ± 75.4 and 435 ± 19.2 days in HOXA9-positive versus HOXA9-negative patients, respectively; Log-rank, p-value = 0.013). This evidence concerns the gene HOXA9 and glioblastoma.